2019 Key Discussions

• Adapting to the changing requirements of market access
• Regional regulatory trends for impacting market penetration
• Digital disruption and impact on RWE, HEOR and market access
• Pricing and Access strategies for branded generics
• Capturing the growth in Asia’s Oncology marketthrough effective pricing and market access approaches
• Challenges and opportunities for key segments e.g. biosimilars, vaccines, anti-infectives
• Value Based Contracting and Risk Share Agreements, and effectiveness of value-based pricing models
• Evaluating out of the box approaches by pharma to fund access to its own medicines
• The use of RWE in drug development and regulatory decision making vs. the use for drug pricing and reimbursement
• Early access environment and early access data
• Pricing and reimbursement models in ASEAN
• Pharma – Insurance partnerships and developments in co pay / co insurance
• Regional regulatory roadmap on reimbursement
• Comparison of RWE across regulatory bodies